Rapport Therapeutics, Inc (RAPP) Diversifiers

Equity · Currency in USD · Last updated Jul 11, 2026

Rapport Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing transformational small molecule medicines for central nervous system (CNS) disorders, including focal epilepsy, peripheral neuropathic pain, bipolar disorder, chronic pain, and hearing disorders. Its lead product candidate, RAP-219, targets TARPy8-containing AMPARs, and the company also develops other molecules such as RAP-199 and nicotinic acetylcholine receptor programs.

Looking to balance out your exposure to RAPP? The ETFs below have the lowest correlation with RAPP — they tend to move on their own, which can help reduce risk when RAPP drops. The stock ideas table highlights individual companies that behave independently from RAPP.

Best Diversifiers for RAPP

1 ETFs have low correlation with RAPP (below 0.3), 0 of which are negatively correlated.

Symbol	Name	Correlation 1Y	Correlation 3Y	Correlation 5Y	Risk / Return Rank	Category	Compare
QQQ	Invesco QQQ ETF	0.28	—	—	64	Nasdaq-100	RAPP vs QQQ

Diversification Analysis

Build a portfolio that complements RAPP

Add RAPP to the Diversification Analyzer to see how it overlaps with your other holdings and which assets balance it best.

Analyze a portfolio with RAPP